Cyclo Therapeutics, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025
I'm PortAI, I can summarize articles.
Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, will present research on Niemann-Pick Disease at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. The presentations will include an oral discussion on the efficacy and safety of Hydroxypropyl-beta-cyclodextrin and a poster on open-label treatment in young patients.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments